AVP receptor antagonists as aquaretics: Review and assessment of clinical data

Joseph G. Verbalis, MD
Departments of Medicine and Physiology, Georgetown University Medical Center, Washington, DC

Correspondence: Joseph G. Verbalis, MD, Interim Chair, Department of Medicine, 5 PHC, Georgetown University Medical Center, 3800 Reservoir Rd., NW, Washington, DC 20007; verbalis@georgetown.edu

Dr. Verbalis reported that he has received grant/research support from Yamanouchi Pharma and Astellas Pharma US, Inc, and is a paid consultant to Astellas Pharma US, Inc; Ferring Pharmaceuticals; Otsuka America Pharmaceutical; and Sanofi-Aventis.

Joseph G. Verbalis, MD
Departments of Medicine and Physiology, Georgetown University Medical Center, Washington, DC

Correspondence: Joseph G. Verbalis, MD, Interim Chair, Department of Medicine, 5 PHC, Georgetown University Medical Center, 3800 Reservoir Rd., NW, Washington, DC 20007; verbalis@georgetown.edu

Dr. Verbalis reported that he has received grant/research support from Yamanouchi Pharma and Astellas Pharma US, Inc, and is a paid consultant to Astellas Pharma US, Inc; Ferring Pharmaceuticals; Otsuka America Pharmaceutical; and Sanofi-Aventis.

Joseph G. Verbalis, MD
Departments of Medicine and Physiology, Georgetown University Medical Center, Washington, DC

Correspondence: Joseph G. Verbalis, MD, Interim Chair, Department of Medicine, 5 PHC, Georgetown University Medical Center, 3800 Reservoir Rd., NW, Washington, DC 20007; verbalis@georgetown.edu

Dr. Verbalis reported that he has received grant/research support from Yamanouchi Pharma and Astellas Pharma US, Inc, and is a paid consultant to Astellas Pharma US, Inc; Ferring Pharmaceuticals; Otsuka America Pharmaceutical; and Sanofi-Aventis.